| Literature DB >> 23873783 |
Mona Johannessen1, Fatemeh Askarian, Maria Sangvik, Johanna E Sollid.
Abstract
The human body is constantly challenged by a variety of commensal and pathogenic micro-organisms that trigger the immune system. Central in the first line of defence is the pattern-recognition receptor (PRR)-induced stimulation of the NFκB pathway, leading to NFκB activation. The subsequent production of pro-inflammatory cytokines and/or antimicrobial peptides results in recruitment of professional phagocytes and bacterial clearance. To overcome this, bacteria have developed mechanisms for targeted interference in every single step in the PRR-NFκB pathway to dampen host inflammatory responses. This review aims to briefly overview the PRR-NFκB pathway in relation to the immune response and give examples of the diverse bacterial evasion mechanisms including changes in the bacterial surface, decoy production and injection of effector molecules. Targeted regulation of inflammatory responses is needed and bacterial molecules developed for immune evasion could provide future anti-inflammatory agents.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23873783 PMCID: PMC3799228 DOI: 10.1099/mic.0.069369-0
Source DB: PubMed Journal: Microbiology ISSN: 1350-0872 Impact factor: 2.777
Fig. 1. Activation of the canonical signalling pathway to NFκB results in nuclear translocation of the transcription factor. NFκB is sequestered in the cytosol in resting cells due to binding to IκB. IκB can be degraded (illustrated by the red cross) upon signalling from the activated NEMO/IKKα/IKKβ complex (IKK complex). The IKK complex can be activated by various stimuli that engage the TCR, TLRs, IL-1R, TNFR and NLRs.
Fig. 2. Engagement of TLRs or NODs by PAMPs results in NFκB activation. PAMPs induce conformational changes in TLRs, resulting in recruitment of appropriate adaptors for example MyD88/MAL. The adaptors recruit the IRAKs which autophosphorylate thereby attracting TRAF6 which again activates the TAK complex resulting in stimulation of the NEMO/IKKα/IKKβ complex (IKK complex). The activated IKK complex phosphorylates IκB, targeting it for ubiquitination and proteasomal degradation. NFκB can then enter the nucleus where it binds to the κB site on appropriate promoters, and the binding can be improved by RPS3. The TAD of p65 recruits co-activators such as CBP/p300 which results in establishment of the transcriptional machinery and transcription of genes encoding proteins involved in immunity. The bacterial surface structure proteins Pg-fimbriae and UspA1/Opa stimulate CXCR4 and CEACAM1 receptors thereby activating cascades that negatively interfere with TLR-induced NFκB activation. Injected E. coli Tir protein inhibits the cascade with a similar mechanism. Nuclear proteins can also be targeted by bacterial effectors. Bacterial effectors can prevent translocation of RPS3 into the nucleus. Similarly, bacterial presence can induce PPAR-γ-mediated nuclear translocation of p65. In the figure, bacterially derived molecules are written in red. The bacterially induced negative interference in signalling pathways or localization of cellular proteins is illustrated with red lines or boxes with red dashed lines, respectively. Ub, ubiquitin; P, phosphate; CBP/p300, CREB binding protein/p300; TAD, transactivation domain.
Immune evasion mechanisms at various steps in the TLR–NFκB pathway
| Targeted step in the pathway | Bacterial species | Bacterial molecule/effector | Mechanism of action | Reference |
| TLRs | Capsule | Masks PAMPs from detection | ||
| Capsule | Masks PAMPs from detection | |||
| Capsule | Masks PAMPs from detection | |||
| Lipid A | ||||
| Lipid A | Induced expression of lipid A modifying enzymes | |||
| Hip1 | Limits the recognition of TLR2 ligands | |||
| SSL3 | Binds to and inhibits TLR2 function | |||
| Pg | Binds CXCR4, thereby counteracting TLR2 effect | |||
| UspA1, Opa | Binds CEACAM1 and recruits SHP-1, which negatively interferes with signalling (dephosphorylates the p85α binding motif of TLR2) | |||
| Tir | Bacterial receptor located in host membrane, recruits SHP-1 that negatively interferes with signalling (interferes with TRAF6 ubiquitination) | |||
| TIRAP/MyD88 | TcpB/Btp1 | Mimics TIRAP, causing its degradation | ||
| TcpC | Binds to MyD88 and negatively interferes with signalling | |||
| IRAKs | LPS | Induces expression of the inhibitory IRAK-M | ||
| TRAF | YopJ | Prevents K63-polyubiquitination of TRAF6 | ||
| OpsI | Deamidates and inactivates the ubiquitin-conjugating enzyme Ubc13 | |||
| TAK/TAB | CagA | Enhances the activity of TAK1 | ||
| NleE | Methylates TAB2 and TAB3, thereby inhibiting the UBD binding ability | Zhang | ||
| IKK complex | YopJ | Acetylates the activation loop of IKKα and IKKβ, thereby preventing their phosphorylation-induced activation | ||
| IpaH9.8 | E3 ligase that polyubiquitinates NEMO, resulting in its degradation | |||
| NleE | Inhibits IKK phosphorylation and activation | Nadler | ||
| IκB | LegK1 | Ser/Thr-kinase-like protein that phosphorylates IκB | ||
| OspG | Inhibits ubiquitin-conjugating enzymes, thereby preventing ubiquitination of IκB | |||
| AvrA | Deubiquitinates IκB | |||
| YopJ | Deubiquitinates K48-IκB | |||
| Deubiquitinates IκB | ||||
| NFκB | OspF | Dual phosphatase that prevents histone H3 phosphorylation in a subset of κB responsive genes | ||
| NleE | Prevents nuclear translocation of p65 and c-Rel | |||
| BopN | Promotes translocation of repressive p50 | |||
| PPAR-γ mediated export of RelA to cytoplasm | ||||
| NleC | Degrades p65 | |||
| NleH1 | Inhibits IKKβ-mediated phosphorylation of RPS3 Ser209, thereby preventing its nuclear translocation | |||
| NleC | Degrades the p300 co-activator |